Evaluation of the safety and benefit of phase I oncology trials for patients with primary CNS tumors

Journal of Clinical Oncology

Volumn 33, Issue 28, 2015, Pages 3186-3192

  Gounder, Mrinal M ^a   Nayak, Lakshmi ^b   Sahebjam, Solmaz ^d   Muzikansky, Alona ^c   Sanchez, Armando J ^a   Desideri, Serena ^e   Ye, Xiaobu ^e   Ivy, S Percy ^f   Nabors, L Burt ^g   Prados, Michael ^h   Grossman, Stuart ^e   De Angelis, Lisa M ^a   Wen, Patrick Y ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ATRASENTAN; BORTEZOMIB; CILENGITIDE; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; HEMOGLOBIN; INCYCLINIDE; IXABEPILONE; KARENITECAN; SORAFENIB; TEMOZOLOMIDE; TERAMEPROCOL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRAIN DISEASE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; DRUG FATALITY; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GLIOMA; HEADACHE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LABORATORY TEST; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MEDICAL RECORD REVIEW; METABOLIC DISORDER; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPIRATORY TRACT DISEASE; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN TOXICITY; SOLID TUMOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ADOLESCENT; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE COURSE; DISEASE FREE SURVIVAL; FACTUAL DATABASE; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PATIENT SAFETY; PATIENT SELECTION; PROCEDURES; REMISSION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS, PHASE I AS TOPIC; DATABASES, FACTUAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PATIENT SAFETY; PATIENT SELECTION; REMISSION INDUCTION; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84944224301     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.1525     Document Type: Article

References (40)

1. Eisenhauer EA, Twelves C, Buyse ME: Phase I Cancer Clinical Trials: A Practical Guide (ed 1). New York, NY, Oxford University Press, 2006
2. Carden CP, Sarker D, Postel-Vinay S, et al: Can molecular biomarker-based patient selection in phase I trials accelerate anticancer drug development? Drug Discov Today 15: 88-97, 2010
3. Gounder MM, Spriggs DR: Inclusion of patients with brain metastases in phase I trials: An unmet need. Clin Cancer Res 17: 3855-3857, 2011
4. Wen PY, Schiff D, Cloughesy TF, et al: It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol 29: 3211-3213, 2011
5. Hyman DM, Eaton AA, Gounder MM, et al: Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials. J Clin Oncol 32: 519-526, 2014
6. Gupta S, Hunsberger S, Boerner SA, et al: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst 104: 1860-1866, 2012
7. Horstmann E, McCabe MS, Grochow L, et al: Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352: 895-904, 2005
8. Olmos D, A'Hern RP, Marsoni S, et al: Patient selection for oncology phase I trials: A multiinstitutional study of prognostic factors. J Clin Oncol 30: 996-1004, 2012
9. National Cancer Institute: Cancer Therapy Evaluation Program: Instructions and Guidelines Clinical Data Update System, 3, 2011. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/cdus.htm
10. Bramwell V, Rouesse J, Steward W, et al: Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma: Reduced local recurrence but no improvement in survival-A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 12: 1137-1149, 1994
11. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990
12. Gilbert MR, Supko JG, Batchelor T, et al: Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 9: 2940-2949, 2003
13. Nabors LB, Supko JG, Rosenfeld M, et al: Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro Oncol 13: 1324-1330, 2011
14. Strumberg D, Richly H, Hilger RA, et al: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23: 965-972, 2005
15. Grossman SA, Ye X, Peereboom D, et al: Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro Oncol 14: 511-517, 2012
16. Goel S, Burris H, Mendelson D, et al: A phase I study of intravenous tetra-O-methyl nordihydroguaiaretic acid in patients with refractory malignancy. J Clin Oncol 25, 2007 (suppl 18S, abstr 3584)
17. Zonnenberg BA, Groenewegen G, Janus TJ, et al: Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: An endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res 9: 2965-2972, 2003
18. Grossman SA, Carson KA, Phuphanich S, et al: Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neuro Oncol 10: 608-616, 2008
19. Schilsky R, Hausheer F, Bertucci D, et al: Phase I trial of karenitecin (KT) administered intravenously daily for five consecutive days in patients with advanced solid tumor using accelerated dose titration. Proc Am Soc Clin Oncol 19: 195a, 2000 (abstr 758)
20. Phuphanich S, Carson KA, Grossman SA, et al: Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro Oncol 10: 617-623, 2008
21. Ryan CW, Vogelzang NJ, Vokes EE, et al: Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res 10: 4406-4411, 2004
22. Peereboom DM, Supko JG, Carson KA, et al: A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas. J Neurooncol 100: 261-268, 2010
23. Abraham J, Agrawal M, Bakke S, et al: Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 21: 1866- 1873, 2003
24. Rudek MA, New P, Mikkelsen T, et al: Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. J Neurooncol 105: 375-381, 2011
25. Syed S, Takimoto C, Hidalgo M, et al: A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res 10: 6512-6521, 2004
26. Phuphanich S, Supko JG, Carson KA, et al: Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol 100: 95-103, 2010
27. Aghajanian C, Soignet S, Dizon DS, et al: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8: 2505-2511, 2002
28. Nabors LB, Mikkelsen T, Rosenfeld SS, et al: Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25: 1651-1657, 2007
29. Eskens FA, Dumez H, Hoekstra R, et al: Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39: 917-926, 2003
30. Ostrom QT, Gittleman H, Liao P, et al: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 16: iv1-63, 2014 (suppl 4)
31. Brennan CW, Verhaak RG, McKenna A, et al: The somatic genomic landscape of glioblastoma. Cell 155: 462-477, 2013
32. Papadatos-Pastos D, Banerji U: Revisiting the role of molecular targeted therapies in patients with brain metastases. J Neurooncol 105: 467-474, 2011
33. Arkenau HT, Olmos D, Ang JE, et al: 90-Days mortality rate in patients treated within the context of a phase-I trial: How should we identify patients who should not go on trial? Eur J Cancer 44: 1536-1540, 2008
34. Hyman DM, Eaton AA, Gounder MM, et al: Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials. Oncotarget [epub ahead of print on January 21, 2015]
35. Bachelot T, Ray-Coquard I, Catimel G, et al: Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 11: 151-156, 2000
36. Roberts TG Jr, Goulart BH, Squitieri L, et al: Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292: 2130-2140, 2004
37. Molife LR, Alam S, Olmos D, et al: Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single centre experience. Ann Oncol 23: 1968-1973, 2012
38. Prados MD, Yung WK, Jaeckle KA, et al: Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro Oncol 6: 44-54, 2004
39. Hellmann A, Rule S, Walewski J, et al: Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma. Clin Pharmacokinet 50: 781-791, 2011
40. Glantz MJ, Cole BF, Forsyth PA, et al: Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors-Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54: 1886-1893, 2000